MedTrace Logo

eMotiph: E-mental Health Solution for Patients With Schizophrenia

NCT05345977 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2024-04-05

No results posted yet for this study

Summary

Although the main objective of current schizophrenia intervention programs is the reduction of symptoms, its rates are around 36%, and recovery rates are 16.5%. Between 30 and 50% of people with schizophrenia obtain little benefit with conventional therapy. They are considered resistant to treatment. Therefore, the development of innovative evidence-based interventions adjunctive to pharmacological and psychological treatment are necessary for improving results in patients with treatment-resistant schizophrenia (TRS). Studies with digital solutions have shown feasibility, acceptability and even preliminary efficacy data. But no earlier published study has focused on TRS.

The eMOTIPH is an innovative solution addressed to TRS and born from the outcomes of the previous study eMOTIPH Part 1 (study of beliefs, needs, and limitations associated with current intervention in TRS patients).

Conditions

Interventions

DEVICE

eMotiph

Mobile application for patients with schizophrenia.

Sponsors & Collaborators

  • Hospital de Sant Pau

    collaborator OTHER

  • Nurogames GmbH

    collaborator UNKNOWN

  • Fundació Tic Salut i Social

    collaborator UNKNOWN

  • Grupo Pulso

    lead INDUSTRY

Principal Investigators

  • Iluminada Corripio, PhD · Hospital de Sant Pau

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-02-28
Completion
2022-02-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05345977 on ClinicalTrials.gov